Please login to the form below

Not currently logged in
Email:
Password:

Ex Sanofi boss joins Boston start-up

Chris Viehbacher joins other industry veterans as the newest board member of PureTech

Viehbacher 

After being ousted from Sanofi as its chief executive last year Chris Viehbacher has found a role as member of the board at a new Boston start-up.

Viehbacher, who spent six years at Sanofi until an apparent falling out with senior board members prompted his departure in October last year, will look to put his experience to good use at the newly founded biotech PureTech.

His move follows an aggressive fundraising campaign for the firm, which has raised $107m in just four months. 

“It is an honour to join this very dynamic and powerful group of both minds and personalities,” Viehbacher said in a statement. 

“PureTech's pipeline of companies is at an exciting inflection point, and I think the talent within the management team and board can achieve great things.”

Prior to taking the top job at Sanofi, he worked for GlaxoSmithKline for 20 years, and ultimately headed up its North America operations. 

He was one of several senior management staffers in-line to take GSK's top job, but ultimately lost out to Sir Andrew Witty in 2008, prompting his move to the French pharma rival. 

PureTech's board includes a number of other veterans from pharma companies such as Merck, Pfizer and Millennium Pharmaceuticals.

Among the 12 companies in PureTech's pipeline are Akili Interactive Labs, which is a collaboration between game designers and neuroscientists to spot signs of the onset of Alzheimer's disease and other neurological conditions.

Article by
Ben Adams

2nd March 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics